Pharmacy Times

Important Points About Chronic Idiopathic Constipation

This article was brought to you by 


About Chronic Idiopathic Constipation
Millions of adults in the United States have chronic constipation.1 When the cause of chronic constipation is not known, the condition is referred to as chronic idiopathic constipation (CIC). A diagnosis of CIC can be made by using the American College of Gastroenterology (ACG) criteria and ruling out potential secondary causes.2,3 According to the ACG, patients may have chronic constipation if they have 2 or more of the following symptoms, lasting at least 3 months3:

Patients May Try Self-Treatment
Patients may self-treat symptoms. Health care providers can offer suggestions to help, such as adding more dietary fiber, increasing liquid consumption, and incorporating more physical activity.2 When these actions are not sufficient, health care providers may recommend over-the-counter products (such as fiber supplements, laxatives, and stool softeners) or prescription medication.2

AMITIZA (lubiprostone) (24 mcg twice daily) for Chronic Idiopathic Constipation in Adults
AMITIZA is a prescription drug approved to treat chronic idiopathic constipation in adults.4 AMITIZA is not a laxative or fiber. AMITIZA increases fluid secretion in the bowel, helping stool to pass.

In two 4-week clinical studies:

AMITIZA (lubiprostone) is indicated for the treatment of chronic idiopathic constipation (24 mcg twice daily) in adults.


Please click here for complete prescribing information for AMITIZA.

Please click here or button above to download a printable patient version.


  1. Higgins PD, Johanson JF. Am J Gastroenterol. 2004;99(4):750-759.
  2. Brandt LJ, Prather CM, Quigley EM, Schiller LR, Schoenfeld P, Talley NJ. Am J Gastroenterol. 2005;100(suppl 1):S5-S22.
  3. American College of Gastroenterology Chronic Constipation Task Force. Am J Gastroenterol. 2005;100(suppl 1):S1-S4.
  4. AMITIZA [package insert]. Bethesda, MD: Sucampo Pharma Americas, Inc.; 2011.
  5. Data on file. Sucampo Pharma Americas, Inc.